FDA approves first MASH drug: Madrigal's Rezdiffra breaks ground in notorious biopharma graveyard

...only the patient studies haven't been finished yet, so it's an approved, experimental drug!

Thanks to Fierce Pharma

For this topic, I need to first thank Fierce Pharma for a long history of sharing news on the pharmaceutical industry. The articles give a great starting point for more critical analysis underneath the words reported. If you check out the analysis that follows, you should be able to find other articles and have some fun dissecting them—to find the real truth on what’s going on. This is the article:

FDA approves first MASH drug: Madrigal's Rezdiffra breaks ground in notorious biopharma graveyard

(recommned you click the article just to scan it over and feel the investor greed ouzzing out).

The article begins:

The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended, as the FDA has approved the first drug for the fatty liver disease.

That begs the question as to how Madrigal managed to achieve what other companies could not? I turned then to a more ‘balanced’ publication, and this is what I found